Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
1.720
-0.030 (-1.71%)
Mar 28, 2025, 4:00 PM EDT - Market closed
Lexaria Bioscience Employees
Lexaria Bioscience had 7 employees as of August 31, 2024. The number of employees increased by 2 or 40.00% compared to the previous year.
Employees
7
Change (1Y)
2
Growth (1Y)
40.00%
Revenue / Employee
$70,989
Profits / Employee
-$1,045,674
Market Cap
30.19M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Aug 31, 2024 | 7 | 2 | 40.00% |
| Aug 31, 2023 | 5 | -2 | -28.57% |
| Aug 31, 2022 | 7 | 1 | 16.67% |
| Aug 31, 2021 | 6 | 2 | 50.00% |
| Aug 31, 2020 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LEXX News
- 12 days ago - Lexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound - TheNewswire
- 12 days ago - Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R) - Accesswire
- 4 weeks ago - The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience - Accesswire
- 4 weeks ago - Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm - Accesswire
- 5 weeks ago - Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide - Accesswire
- 6 weeks ago - Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy - Accesswire
- 7 weeks ago - Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway - TheNewswire
- 7 weeks ago - Lexaria Updates its Ongoing Human Study GLP-1-H24-4 - TheNewswire